José Ignacio
Fernández de Trocóniz Fernández
Catedrático de Universidad
Publicaciones (205) Publicaciones de José Ignacio Fernández de Trocóniz Fernández
2024
-
Disentangling Anti-Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab
Clinical Pharmacology and Therapeutics
-
Foxp3 inhibitory peptide encapsulated in a novel CD25-targeted nanoliposome promotes efficient tumor regression in mice
Acta Pharmacologica Sinica
-
How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children
Antimicrobial Agents and Chemotherapy, Vol. 68, Núm. 6
-
Is estimated exposure an accurate surrogate for measured fludarabine levels in patients with CAR T-cell therapy?
Blood Advances
-
Mechanism-Based Modeling of Perioperative Variations in Hemoglobin Concentration in Patients Undergoing Laparoscopic Surgery
Anesthesia and Analgesia, Vol. 138, Núm. 1, pp. 141-151
-
Model-Based Assessment of the Liver Safety Profile of Acetaminophen to Support its Combination Use with Topical Diclofenac in Mild-to-Moderate Osteoarthritis Pain
Pain and Therapy, Vol. 13, Núm. 1, pp. 127-143
-
Model-Based Bioequivalence Analysis to Assess and Predict the Relative Bioavailability of Valproic Acid Formulations
European Journal of Drug Metabolism and Pharmacokinetics, Vol. 49, Núm. 4, pp. 507-516
-
Model-Based Meta-Analysis Supporting the Combination of Acetaminophen and Topical Diclofenac in Acute Pain: A Therapy for Mild-to-Moderate Osteoarthritis Pain?
Pain and Therapy, Vol. 13, Núm. 1, pp. 145-159
-
Pharmacokinetic/pharmacodynamic modeling of cortical dopamine concentrations after quetiapine lipid core nanocapsules administration to schizophrenia phenotyped rats
CPT: Pharmacometrics and Systems Pharmacology, Vol. 13, Núm. 4, pp. 638-648
-
The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model
Pediatric Drugs, Vol. 26, Núm. 3, pp. 331-346
2023
-
A physiologically based pharmacokinetic model for V937 oncolytic virus in mice
Frontiers in Pharmacology, Vol. 14
-
Assessment of Clinical Response to V937 Oncolytic Virus After Intravenous or Intratumoral Administration Using Physiologically-Based Modeling
Clinical Pharmacology and Therapeutics, Vol. 114, Núm. 3, pp. 623-632
-
Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironment
PLoS Computational Biology, Vol. 19, Núm. 10
-
Population Pharmacodynamic Modelling of the CD19+ Suppression Effects of Rituximab in Paediatric Patients with Neurological and Autoimmune Diseases
Pharmaceutics, Vol. 15, Núm. 11
-
Population pharmacokinetics of sublingually administered tacrolimus in infants and young children with liver transplantation
British Journal of Clinical Pharmacology, Vol. 89, Núm. 3, pp. 1115-1126
-
Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation
European Journal of Pharmaceutical Sciences, Vol. 183
2022
-
A method to assess model-based bioequivalence
Revista Colombiana de Ciencias Químico-Farmacéuticas, Vol. 51, Núm. 3, pp. 1578-1579
-
Comparison of two pharmacokinetic–pharmacodynamic models of rocuronium bromide during profound neuromuscular block: analysis of estimated and measured post-tetanic count effect
British Journal of Anaesthesia, Vol. 128, Núm. 3, pp. 473-481
-
IMI2-PainCare-BioPain-RCT1: study protocol for a randomized, double-blind, placebo-controlled, crossover, multi-center trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by peripheral nerve excitability testing (NET)
Trials, Vol. 23, Núm. 1
-
IMI2-PainCare-BioPain-RCT2 protocol: a randomized, double-blind, placebo-controlled, crossover, multicenter trial in healthy subjects to investigate the effects of lacosamide, pregabalin, and tapentadol on biomarkers of pain processing observed by non-invasive neurophysiological measurements of human spinal cord and brainstem activity
Trials, Vol. 23, Núm. 1